Geneva, June 22 -- International Clinical Trials Registry received information related to the study (ChiCTR2600126576) titled 'A Study of Iparomlimab and Tuvonralimab as Neoadjuvant Therapy Before Concurrent Chemoradiotherapy and Maintenance Therapy After Concurrent Chemoradiotherapy in Advanced Cervical Cancer' on June 11.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Hubei Cancer Hospital
Condition:
uterine cervical cancer
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-06-16
Target Sample Size: Experimental group:45;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=326324
Disclaimer: Curated by HT Syndication....